Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777981 | 0.82 | KMO (0.35) | GAA | |
| SCHEMBL1778959 | 0.81 | PLA2G10 (0.37) | FAAHLMNA | |
| SCHEMBL1775683 | 0.79 | ADORA1 (0.43) | LMNASMN1; SMN2CYP1A2KMT2AGAA | |
| SCHEMBL15300178 | 0.77 | CYP1A2 (0.44) | FAAHLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19897430 | 0.76 | CYP1A2 (0.42) | FAAHLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1233876 | 0.75 | CYP1A2 (0.41) | FAAHLMNANPC1RAB9ASMN1; SMN2 | |
| Ozone SCHEMBL7422852 | 0.72 | KDM4E (0.39) | FAAHLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15519242 | 0.71 | CYP1A2 (0.46) | FAAHLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1233517 | 0.71 | BAZ2B (0.54) | FAAHLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15300116 | 0.70 | KDM4E (0.46) | NPC1RAB9ASMN1; SMN2MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943636-B2 | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | IL2, IL4, IFNG | FAAH 4315/4885PIK3CA 1545/4885LMNA 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.